Enveric Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies for Lead Candidate EB-373, a Next Generation Psilocin Prodrug Targeting Psychiatric Disorders – Medical Marijuana Program Connection

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced initiation of Good Laboratory Practice (GLP)-toxicology and safety pharmacology studies for lead prodrug candidate EB-373, the company’s next generation psilocin prodrug being developed for the treatment of ps

Source link

• SEO Powered Content & PR Distribution. Get Amplified Today.
• PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
• PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
• PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
• PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
• Source: https://mmpconnect.com/enveric-biosciences-initiates-glp-toxicology-amp-safety-pharmacology-studies-for-lead-candidate-eb-373-a-next-generation-psilocin-prodrug-targeting-psychiatric-disorders/?utm_source=rss&utm_medium=rss&utm_campaign=enveric-biosciences-initiates-glp-toxicology-amp-safety-pharmacology-studies-for-lead-candidate-eb-373-a-next-generation-psilocin-prodrug-targeting-psychiatric-disorders